{"symbol":"BMY","fiscalQuarter":"Q2-2016","reportDate":"2016-07-28","reportTime":"BMO","status":"reported","company":{"name":"Bristol-Myers Squibb Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/BMY/earnings/Q2-2016","postBrief":{"headline":"Bristol Myers Squibb Beats on EPS, Stock Down 2.37%","keyNumbers":[{"metric":"EPS","actual":"$0.69","expected":"N/A","surprise":"+2.68%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management expressed satisfaction with the EPS performance despite the lack of revenue guidance.","They emphasized their commitment to ongoing research and development."],"summary":"Overall, management highlighted the positive EPS surprise as a sign of operational efficiency. However, they did not provide specific revenue guidance."},"guidanceChanges":{"summary":"No guidance data is available for this quarter.","changes":[]},"whatItMeans":"Bristol Myers Squibb's earnings report showed a positive EPS surprise, indicating better-than-expected profitability. However, the stock fell by 2.37%, likely due to the absence of revenue figures and guidance, which left investors uncertain about future performance.","metaDescription":"Bristol Myers Squibb (BMY) Q2 2016 earnings: EPS beat by 2.68%. Stock down 2.37%. Full breakdown."}}